Clotrimazole (Glenmark Clotrimazole Vaginal)
Clotrimazole
Glenmark Pharmaceuticals South Africa (Pty) Ltd
Registration
- Applicant
- Glenmark Pharmaceuticals South Africa (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Glenmark clotrimazole 6 vaginal tablet EACH VAGINAL TABLET CONTAINS CLOTRIMAZOLE 100,0 MG | 6Tablet | 32004132/20.2.2/0041 | Registered | Not determined | None |
| Glenmark clotrimazole 1 vaginal tablet EACH VAGINAL TABLET CONTAINS CLOTRIMAZOLE 500,0 mg | 1Tablet | 32004232/20.2.2/0042 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Clotrimazole
- except when intended for application to the skin (S1) and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S1)
Consolidated Schedules 06 July 2026, lines 5859 to 5860
S1: Clotrimazole
- when intended for human vaginal use specifically for the treatment of recurrent vaginal candidiasis; (S4) and
- when intended for application to the skin. (S4)
Consolidated Schedules 06 July 2026, lines 330 to 335
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
1-[(2-Chlorophenyl)-diphenylmethyl]imidazole
Drag to rotate. Structure from PubChem CID 2812.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.